- Email: [email protected]
76: The development of an international standard set of outcomes measures for evaluating the treatment of overactive bladder
ajog.org
Non-Oral Posters cases of ovarian endometriomas. The infiltrative extent of ovarian endometrioma has not been previously defined in the literature. We aimed to identify the histologic forms of ovarian endometriosis and its relations to clinical symptoms of pain and infertility, to the proliferative activity (Ki-67) and to the molecular expression of apoptotic mechanisms (p53 and Bcl-2). MATERIALS AND METHODS: This is a retrospective cohort study including 80 consecutive women who had laparoscopic and histologic confirmation of ovarian endometriosis. The study was approved by the Sao University Medical School Review Board (0525/ 11). The specimens were classified according to the presence of the disease in the surface of the ovaries (superficial disease), in the capsule of the ovarian cyst (cystic ovarian endometriosis) or when the disease infiltrated the ovarian parenchyma (intra-parenchymatous ovarian disease). RESULTS: The most frequent form of ovarian endometriosis was the cystic disease (72.5%), followed by intra-parenchymatous ovarian endometriosis (22.5%) and superficial ovarian endometriosis (5%). No associations were found among symptoms, concomitant disease, markers expression and the histologic types of ovarian endometriosis. CONCLUSION: Ovarian endometriosis has three distinct infiltrative extents as confirmed by histology. Although this pilot study did not show any correlation between infiltrative extent, clinical manifestation and to the markers expression., future studies involving larger sample sizes and other markers should be considered. DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS: Mauricio S. Abrao: Nothing to disclose; luiz F. C. Fernandes: Nothing to disclose; Lidia Myung: Nothing to disclose; Katia Pincerato: Nothing to disclose.
76 The development of an international standard set of outcomes measures for evaluating the treatment of overactive bladder S. J. Pulliam1, C. E. Foust-Wright2, A. Morse3
1 OB/GYN, University of North Carolina, Chapel Hill, NC, 2OB/GYN, Maine Medical Center, Portland, ME, 3OB/GYN, Harvard University Medical School, Boston, MA
OBJECTIVES: To define a minimum Standard Set of outcome measures and case-mix factors for evaluating the care of patients with overactive bladder (OAB). Standardized measures enable the comparison of outcomes across providers and treatment paradigms providing valuable information for improving care quality and efficacy. MATERIALS AND METHODS: The International Consortium for Health Outcomes Measurement (ICHOM) convened an international Working Group (WG) of leading clinicians and patients representing 7 countries on 3 continents with funding from the International Urogynecological Association. The WG met for 8 structured teleconferences. Consensus was determined by a modified Delphi Process and discussions were supported by literature review and consumer input. RESULTS: The Standard Set measures the outcomes of care for adult patients seeking treatment for OAB, excluding residents of long-term care facilities. The WG focused on treatment outcomes that were found to be most important to patients and selected disease severity, physical functioning, emotional health, impact of disease and treatment on quality of life, and success of treatment as key outcome domains to include in the set. Demographic information and case mix factors that may influence these outcomes are also included. CONCLUSION: A standardized outcome set for the evaluation of clinical care of patients with OAB was developed by an international WG comprised of clinicians and patients. We believe that this set is appropriate for use by all health providers caring for patients with OAB, regardless of specialty or geographic location, and provides key data for quality improvement activities and research.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS: Samantha J. Pulliam: Nothing to disclose; Caroline E. Foust-Wright: Nothing to disclose; Abraham Morse: Nothing to disclose.
S618 American Journal of Obstetrics & Gynecology Supplement to MARCH 2017
Non-Oral Posters cases of ovarian endometriomas. The infiltrative extent of ovarian endometrioma has not been previously defined in the literature. We aimed to identify the histologic forms of ovarian endometriosis and its relations to clinical symptoms of pain and infertility, to the proliferative activity (Ki-67) and to the molecular expression of apoptotic mechanisms (p53 and Bcl-2). MATERIALS AND METHODS: This is a retrospective cohort study including 80 consecutive women who had laparoscopic and histologic confirmation of ovarian endometriosis. The study was approved by the Sao University Medical School Review Board (0525/ 11). The specimens were classified according to the presence of the disease in the surface of the ovaries (superficial disease), in the capsule of the ovarian cyst (cystic ovarian endometriosis) or when the disease infiltrated the ovarian parenchyma (intra-parenchymatous ovarian disease). RESULTS: The most frequent form of ovarian endometriosis was the cystic disease (72.5%), followed by intra-parenchymatous ovarian endometriosis (22.5%) and superficial ovarian endometriosis (5%). No associations were found among symptoms, concomitant disease, markers expression and the histologic types of ovarian endometriosis. CONCLUSION: Ovarian endometriosis has three distinct infiltrative extents as confirmed by histology. Although this pilot study did not show any correlation between infiltrative extent, clinical manifestation and to the markers expression., future studies involving larger sample sizes and other markers should be considered. DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS: Mauricio S. Abrao: Nothing to disclose; luiz F. C. Fernandes: Nothing to disclose; Lidia Myung: Nothing to disclose; Katia Pincerato: Nothing to disclose.
76 The development of an international standard set of outcomes measures for evaluating the treatment of overactive bladder S. J. Pulliam1, C. E. Foust-Wright2, A. Morse3
1 OB/GYN, University of North Carolina, Chapel Hill, NC, 2OB/GYN, Maine Medical Center, Portland, ME, 3OB/GYN, Harvard University Medical School, Boston, MA
OBJECTIVES: To define a minimum Standard Set of outcome measures and case-mix factors for evaluating the care of patients with overactive bladder (OAB). Standardized measures enable the comparison of outcomes across providers and treatment paradigms providing valuable information for improving care quality and efficacy. MATERIALS AND METHODS: The International Consortium for Health Outcomes Measurement (ICHOM) convened an international Working Group (WG) of leading clinicians and patients representing 7 countries on 3 continents with funding from the International Urogynecological Association. The WG met for 8 structured teleconferences. Consensus was determined by a modified Delphi Process and discussions were supported by literature review and consumer input. RESULTS: The Standard Set measures the outcomes of care for adult patients seeking treatment for OAB, excluding residents of long-term care facilities. The WG focused on treatment outcomes that were found to be most important to patients and selected disease severity, physical functioning, emotional health, impact of disease and treatment on quality of life, and success of treatment as key outcome domains to include in the set. Demographic information and case mix factors that may influence these outcomes are also included. CONCLUSION: A standardized outcome set for the evaluation of clinical care of patients with OAB was developed by an international WG comprised of clinicians and patients. We believe that this set is appropriate for use by all health providers caring for patients with OAB, regardless of specialty or geographic location, and provides key data for quality improvement activities and research.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS: Samantha J. Pulliam: Nothing to disclose; Caroline E. Foust-Wright: Nothing to disclose; Abraham Morse: Nothing to disclose.
S618 American Journal of Obstetrics & Gynecology Supplement to MARCH 2017